Kent Imaging Becomes Net Health’s First Integrated Imaging Device

First partner brings real-time decision-making for wound care plus innovative and non-invasive oxygenation imaging

Pittsburgh – January 26, 2021 – Tissue Analytics, a Net Health company that provides software solutions for the wound care industry, announced today that the company has partnered with Calgary, Canada-based Kent Imaging, Inc. to be the first member of its new application programming interface (APIs) program.  The API was announced in December, with additional partners scheduled to join in the coming months.

Kent Imaging is a leading innovator in oxygenation imaging that develops, manufactures, and markets medical technology that supports real-time decision making in wound care, vascular and surgical subspecialties.  Tissue Analytics is the market leader in wound imaging, providing artificial intelligence-powered software solutions that serve hospitals, post-acute facilities, and clinical trials.

The new agreement with Net Health enables Kent Imaging to expand the footprint and interoperability of their flagship product, SnapshotNIR®, which utilizes near-infrared light to determine tissue oxygen saturation (StO2), a key indicator of tissue health. Through the technology, clinicians are better able to plan appropriate interventions, reduce complications and improve outcomes.

“Our integration with Kent Imaging is the perfect example of the value of Net Health’s API,” said Kevin Keenahan, Senior Vice President of Business Development for Net Health and a founder of Tissue Analytics. “This agreement highlights how and why our API can benefit a wide range of industry innovators.”

Net Health’s API also enables vendors to benefit from the company’s downstream connections with leading wound care electronic health record (EHR) systems, including Net Health® Wound Care (formerly WoundExpert®), the most widely used wound care-specific EHR in the nation, as well as Cerner, Epic and others. 

“Kent Imaging is excited to work with Net Health through the Tissue Analytics API to ensure that critical information on the state of a wound is incorporated into the patient record at every visit,” said Pierre Lemire, CEO of Kent Imaging. “The integrated product streamlines workflow while providing documented tissue oxygenation data to complete the patient chart. By making our product interoperable with leading EMRs, we are ensuring that a wide range of clinicians and patients can access our innovative technology.”

Dr. Luc Marengere, Managing Partner, TVM Capital Life Science and member of the Board of Directors at Kent Imaging, also applauds the new partnership. “Collaborating with Net Health, a leader in the wound care market, will support the accelerated adoption of the SnapshotNIR technology,” says Marengere. “Clear unmet needs in wound care, such as non-healing wounds, are a huge burden with respect to patient outcome and ever-rising healthcare costs. Delivering innovative solutions through partnership provides synergy in responding positively to this growing concern.”

For more information, visit and

About Net Health

Net Health provides software and analytics for specialty medical providers across the continuum of care. Net Health’s interoperable solutions ensure compliance, improve outcomes, empower providers and inspire care. The company serves over 14,000 facilities, including 98 percent of the largest hospital chains, two-thirds of skilled nursing facilities and many leading hospice organizations and private practices. Net Health is a portfolio company of The Carlyle Group, Level Equity and Silversmith Capital Partners.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading innovator in oxygenation imaging, who develops, manufactures, and markets medical technology that supports real-time decision making in wound care, vascular and surgical subspecialties. Kent holds multiple patents in oxygen imaging technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit

PR Newswire Link  –

For more information:

Sandra Jenks, Kent Imaging 403-455-7610

Kent Imaging Inc. Receives FDA 510(k) Clearance on SnapshotNIR V3.0

CALGARY, January 6, 2021 /EIN Presswire/ – Kent Imaging announced today the FDA 510(k) clearance for SnapshotNIR V3.0 (KD204) – now available for shipping. This upgrade provides significant feature enhancements to the imaging technology that advances tissue assessment in acute and chronic wounds. The multitude of advancements include the ability to image most skin tones (overcoming the melanin barrier), linear and surface area wound measurements, easy report generation with image comparisons, and enhanced patient file management, to name a few.

SnapshotNIR utilizes near infrared light to determine tissue oxygen saturation (StO2), which is a key indicator of tissue health. Ideal for microcirculation assessment, it conveys a comprehensive picture of the healing capacity of wounds or surgical tissue. This critical information is used to support clinical judgement in choosing, evaluating, and tracking treatment and surgical options throughout the care continuum.

“We are excited to release this enhanced version of SnapshotNIR as part of Kent’s dedication to bringing innovation to this critical market. Robust features asked for by front-line wound care specialists and reconstructive surgeons have been incorporated, delivering a product that can easily track and document wound healing progress and support therapeutic decisions,” noted Pierre Lemire, CEO. “SnapshotNIR V3.0 continues to support the goal of delivering on solutions that aid wound care and surgical specialists in improving patient outcomes and reducing complications.”

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading innovator in oxygenation imaging, who develops, manufactures, and markets medical technology that supports real-time decision making in wound care, vascular and surgical sub-specialties. Kent holds multiple patents in oxygen imaging technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit

SnapshotNIR featured in interview with Dr. Windy Cole on the Wound Care Learning Network

Curious how SnapshotNIR fits the theragnostic definition? Or how SnapshotNIR can be used as a non-invasive vascular assessment to improve delivery of quality care? Or how this new and novel technology is being used in clinical research and private practice? The Wound Care Learning Network chatted with Dr. Windy Cole, DPM, Adjunct Professor and Director of Wound Care Research at Kent State University College of Podiatric Medicine, to answer these questions based on her experience using the device.

For answers, watch the video spotlight on SnapshotNIR here.

SnapshotNIR Used to Identify Patterns of StO2 in Wound Healing

In a retrospective study published in Wounds (October 2020), Adam Landsman, DPM, PHD, set out to identify if distinct patterns of tissue oxygen saturation (StO2) in the wound and periwound tissues are associated with wound healing. Using near infrared spectroscopy (NIRS), 25 patients with diabetic foot ulcers or venous leg ulcers were imaged throughout their course of therapy. Retrospectively, the images were analzed for common patterns in StO2 that may predict whether or not a wound would heal.

Read the full article, Visualization of Wound Healing Progression with Near Infrared Spectroscopy: A Retrospective Study, to learn more about Dr. Landsman’s findings, including the four stages identified as H.I.N.T.

Kent Imaging and SerenaGroup® Research Foundation awarded prestigious AICE grant

September 22, 2020. Kent Imaging and SerenaGroup® Research Foundation, have received the prestigious Accelerating Innovations into Care (AICE)Market Access grant from Alberta Innovates, a research and innovation agency sponsored by the province of Alberta, Canada. AICE supports companies in commercializing innovative digital health technologies. The award will fund clinical trials investigating the novel diagnostic technology developed by Kent Imaging utilizing near infrared spectroscopy (SnapshotNIR). Kent has partnered with SerenaGroup® Research Foundation to conduct this pivotal research.

Near infrared spectroscopy measures oxygen levels in tissue in real time without the need for injected dyes or invasive probes.  SnapshotNIR captures the image without patient contact. The colors displayed on the screen correspond to the degree of tissue oxygenation:  blue represents low oxygen levels and red represents high.  At present, advanced wound and hyperbaric centers use transcutaneous oxygen (TCOM) to measure oxygenation; however, TCOM has numerous drawbacks: the results are operator dependent, it requires heated leads that are attached to the skin and the procedure takes an hour to complete.

The AICE grant will fund a multicenter head-to-head clinical trial comparing SnapshotNIR to TCOM. In addition, correlation between the SnapshotNIR readings and healing outcomes will allow the investigators to predict the best interventions for patients with diminished oxygenation. “Health innovators often face headwinds in generating the evidence necessary for implementing new solutions. The data generated in this trial will accelerate the path to impact for SnapshotNIR, and is fully aligned with our digital health strategy,” shared Tim Murphy, VP Health at Alberta Innovates.

“This new technology from Kent Imaging will allow clinicians to rapidly assess tissue oxygenation in patients with chronic wounds, which will avoid delays in diagnosis and treatment,” said Dr. Tomas Serena, Director of the SerenaGroup® Research Foundation. “I believe that SnapshotNIR will play a key role in limb preservation in our diabetic patients, allowing woundologists to identify the patients who will benefit from advanced modalities such as for hyperbaric oxygen therapy.”

“We are very excited to be working with Dr. Tomas Serena and the SerenaGroup® Research Foundation to establish definitively the value of SnapshotNIR in the prediction of wound healing. Kent Imaging’s goal is to provide innovative technology that helps physicians to heal wounds, improve outcomes and significantly reduce amputations. This study will take us a long way towards meeting this goal,” said Pierre Lemire, CEO at Kent Imaging. “We also want to acknowledge the ongoing support of the Alberta Government in bringing this paradigm changing technology to market.”

About Kent Imaging

Kent Imaging Inc., a Canadian company located in Calgary, Alberta, and leading innovator in oxygenation imaging, designs and manufactures imaging technology that employs near infrared spectroscopy to measure tissue oxygen saturation. The oxygenation information provides immediate insight into tissue viability supporting real-time decision making in wound care, vascular and surgical specialties to aid in the delivery of positive patient outcomes throughout the care continuum.  For more information about Kent Imaging, visit

About SerenaGroup® Research Foundation

The SerenaGroup® Research Foundation, a leader in wound healing research, conducts eight to nine clinical trials each year and publishes a dozen manuscripts annually. Dr. Serena has been the lead or Principal Investigator in over 100 clinical trials, including gene therapy, dressings, growth factors, topical and parenteral antibiotics, and CTP therapy.  His team has led the development of diagnostic imaging and biomarkers in the field of wound healing.  

About Alberta Innovates

Alberta Innovates invests in research, innovation and entrepreneurship to drive provincial economic growth and diversity. We ignite the power of innovation through our work with researchers, industry and entrepreneurs to move Alberta to a lower-carbon future, enhance the responsible use of land and water, and contribute to the improved health and well-being of Albertans.